Said the rep who didn’t get the offer. Go away!Yep, incredible results for some of the most intractable epilepsy patients. I've sold in epilepsy for a number of years and know the market well. With these kind of results and assuming no major safety issues crop up, there is no doubt in my mind, that most clinicians would choose ZX008 sooner in the course of treatment than Epidiolex.
Happen to agree with the reasonable post regarding Zogenix' drug and gotta laugh at how defensive some of you get. Rather than post an intelligent response, all you've got is "....you didn't get the job"... Your lame response says a lot about you, and it's not good. Hope you're not one of the few that got hired. LGS and Dravet patients deserve better. Grow the fuck up.Said the rep who didn’t get the offer. Go away!
This keeps coming up in my territory. My MSL knows nothing. I think we are in trouble here.
Fintepla jobs just posted on LinkedIn. Let the exodus begin!
These medications will not compete with each other in the long run.
Safety will trump who is started on what first and doctors will be very conservative out of the gate with Zogenix mediation. They will be agressive with Epidiolex.
The Epidiolex data is better than you think for long term efficacy.
anybody get an offer yet?
